Helicobacter pylori is a gram-negative microorganism that causes gastritis and gastric carcinoma (11, 12, 13) , infects through the intake of food, and attaches to the gastric and duodenal mucous membranes (14, 27) . Once attached, it remains for several decades and is not eliminated naturally. The ease with which it reinfects is the major cause of chronic gastritis. To remove H. pylori, antibiotic drugs (e.g., amoxicillin and clarithromycin), restrainers of proton pumping (e.g., omeprazole), and gastric acid removers (e.g., magnesium) have been used. H. pylori develops resistance to antibiotics, however, and stomach acid removers do not solve the infection problem.
It has been well documented that probiotic lactic acid-producing bacteria (LAB) can develop antagonistic activity against various human pathogens (3, 24). Certain LAB synthesize antimicrobial compounds that are related to the bacteriocin family (16) . Other such compounds synthesized by LAB are well-known metabolic end products of lactic acid fermentation, such as lactic and acetic acids (21) and hydrogen peroxide, or are as yet unidentified (4) . Because LAB are known to exist in the intestines and exert antibacterial activity on intestinal pathogens and because the stomach is a very harsh environment, with low pH and the presence of pepsin, most researchers have assumed that LAB cannot inhibit gastric pathogens. Recently, however, Lactobacillus salivarius (1), Lactobacillus acidophilus (3), and Bacillus subtilis (23) were found to produce antibacterial materials other than lactic acid against H. pylori. In human volunteers, the spent culture supernatants (SCSs) of the human L. acidophilus strain LB and Lactobacillus gasseri OLL2716 (LG21) were active against H. pylori (10, 20, 25) .
In an effort to find new LAB with activity against H. pylori, more than 100 LAB were isolated from infant feces; one isolate was selected based on its strong inhibitory activity on H. pylori growth and on the adherence of H. pylori to the glycolipid, the binding moiety in the stomach (Lewis antigen isolated from reticulocytes of human O-type blood [5, 14, 15, 18] ), as has been described in a previous paper (18) . This isolate was identified as Weissella confusa, and its 16S rRNA sequence was registered in GenBank under the accession no. AF477495. The genus Weissella was separated recently from the genus Lactobacillus due to developments in DNA technology (28) . W. confusa (previously known as Lactobacillus confusus and originally known as Lactobacillus coprophilus) is present in the normal microflora of human intestines (22, 28, 29, 30) and has been isolated worldwide from foods such as Greek salami (26), Malaysian chili bo (19) , and Mexican pozol (2) . However, no strain in this genus has yet been developed as a probiotic. In this study, the anti-H. pylori functions of W. confusa strain PL9001 were characterized.
H. pylori ATCC 43504 was grown on brucella solid medium containing amphotericin B (2.5 g/ml; Fungizone) and Skirrow's supplement (2.5 IU of polymyxin B/ml, 10 g of vancomycin/ml, 5 g of trimethoprim/ml) and supplemented with 10% horse serum in 5 to 10% CO 2 . The inhibitory activity of the SCS on the growth of H. pylori was assayed with a well test by adding 100 l of the SCS of PL9001 to each well formed with a sterilized Pasteur pipette on a solid medium inoculated with H. pylori. The SCS was subjected to low pH (pH 2), pepsin (30 U/ml), proteinase K (0.1 g/ml), or heat treatment. After colonies appeared, the diameter of the inhibited growth zone was measured.
The ability of PL9001 to bind to human gastric-cell line MKN-45 cells was observed by Gram staining and scanning electron microscopy (SEM) (model JSM-5200; Jeol, Tokyo, Japan). MKN-45 cells were cultured in RPMI 1640 medium (Gibco-BRL, New York, N.Y.) containing 2 g of sodium bicarbonate/liter, 10% heat-inactivated fetal bovine serum, and antibiotic-antimycotic (pH 7.2) in a 30-mm-diameter dish (Nunc, Inc., Naperville, Ill.) for Gram staining or in a Lab Tak chamber slide system (Nunc, Inc.) for SEM by inoculating 3 ϫ 10 5 viable cells into 2 ml of culture medium. A 6-day confluent monolayer was washed twice with 2 ml of phosphate-buffered saline before the adhesion assay. One hundred microliters of PL9001 (10 7 CFU in 1 ml) was added to 2 ml of a complete MKN medium and incubated at 37°C in a 5% CO 2 incubator. After incubation for 60 min, the monolayer was washed twice with sterile phosphate-buffered saline (pH 7.4) and fixed with methanol. Cells were examined under a light microscope after Gram staining or by SEM. To observe the effect of the SCS on H. pylori, 1 ml of the SCS was mixed with the same volume of H. pylori in brucella broth. After various incubation times, Among the 100 LAB isolated from infant feces, several isolates that showed good inhibitory activity on the adherence of H. pylori to glycolipid spotted on a thin-layer chromatography plate were selected. One isolate (PL9001), which showed the best inhibitory activity on the growth of H. pylori in a well test, was selected and characterized further. A growth inhibition zone was observed even after the SCS of PL9001 was subjected to pH 2, pH 4, pepsin, proteinase K, or heat treatment (data not shown). When H. pylori was treated with the SCS, the cells changed from helical form (Fig. 1A) to coccoid form and became necrotic (Fig. 1C) , even after treatment with the neutralized SCS (Fig. 1D) . A similar coccoid form was observed with H. pylori treated with amoxicillin (Fig. 1B) ; others have previously observed the same result after treatment with the SCS of L. acidophilus (10) , and this form is known to result in a loss of infectivity (6, 17) . Because the neutralized SCS had the same effect, there must be a factor(s) for necrosis in addition to lactic acid and low pH. The antibacterial activity was stable after low pH, pepsin, proteinase, or heat treatment; thus, the bacteriocin(s) produced by PL9001 seems to belong to the class II bacteriocins, nonproteinaceous materials that rupture the cell wall (16). PL9001 can bind to gastric cells ( Fig. 2A and B) , and this binding ability remained in the nonviable cells heated at 75°C for 15 min (Fig. 2C and D) . As observed by SEM, many cells with the characteristic club shape of W. confusa were found on the surface of MKN-45 cells (Fig. 3) . The prevention of the adherence of H. pylori by PL9001 was confirmed with FITCconjugated antibody. As shown in Fig. 4 , both live and nonviable PL9001 inhibited the binding of H. pylori to MKN-45 cells. The binding activity of nonviable PL9001 suggests that PL9001 binds directly to the stomach via a mechanism similar to that involved in the binding of LAB to the intestinal epithelial cells (7, 8, 9) and that nonviable as well as viable PL9001 can prevent the adherence of H. pylori to the stomach. The results of this study show that strain PL9001 has a dual inhibitory activity on H. pylori-bactericidal activity and prevention of adherence to gastric mucous cells-and has the potential to be developed as a new probiotic for the stomach.
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